A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.
Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.
In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.
A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
This case describes management of a 61-year-old male with a history of chronic liver diseases and COPD who developed a posttransplant lymphoproliferative disorder 10 years after a liver transplant.
Investigators assessed the impact of advances over time in the treatment of Hodgkin lymphoma on all-cause mortality in patients with Hodgkin lymphoma who received radiotherapy alone or with chemotherapy.
Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab VedotinJune 29, 2017
Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.
Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.
Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.
There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.
Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.
Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.
Early MRI-based screening may reduce breast cancer mortality among women treated with radiation therapy for Hodgkin lymphoma.
Model Demonstrates Benefits of MRI Screening for Breast Cancer in Survivors of Childhood Hodgkin LymphomaMarch 15, 2016
Female survivors of childhood Hodgkin lymphoma (HL) who received chest radiation can reduce their risk of breast cancer through early screening.
African-American pediatric patients with Hodgkin lymphoma still display a considerable survival disparity when compared to their white and Hispanic peers.
Identifying and reducing barriers to recommended treatment and surveillance in those at higher risk of mortality is essential.
Adolescent and Young-adult Survivors of Hodgkin Lymphoma May Not Adhere to Follow-up RecommendationsJanuary 18, 2016
Within the first year posttreatment, more than half of Hodgkin lymphoma survivors did not receive all recommended care. However, 96% had their recommended oncology visits and 70% had the recommended laboratory tests within the first 5 years.
Hodgkin lymphoma survivors have an increased risk of secondary cancer compared with the general population, even for those receiving more recent treatments.
Radiotherapy is the most effective single modality for local control of Hodgkin lymphoma. Involved site radiotherapy is a recent innovation intended to reduce the risk of late effects—an urgent goal, particularly for adolescent and young adult patients.
A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.
PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.
TARC levels correlated with PET-normalization in certain patients with Hodgkin lymphoma treated with brentuximab vedotin, a study indicates.
A study has reaffirmed the importance of genetically defined PD-1 mediated immune evasion for patients with Hodgkin lymphoma.
Researchers showed that an increased risk of cardiovascular disease is quantified at specific dose levels of radiation as well as anthracycline exposure.
Childhood cancer survivors are at heightened risk of a wide range of autoimmune diseases. Diabetes and Addison's disease make up almost half of the excess cases, according to the findings.
Survivors of Hodgkin lymphoma have an increased risk for developing various late complications, including cardiovascular disease.
Living in overcrowded conditions appears to protect children and young adults against developing a subtype of Hodgkin lymphoma. The protective effect suggests that infections earlier in life may stimulate the immune system to deal with future infections and cancerous cells more efficiently.
Brentuximab vedotin is proven an effective and safe first course of treatment for older patients with Hodgkin lymphoma who are not candidates for chemotherapy.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|